



Review Article

Literature-Based Review on Insights and Developments of Epileptic Activities

Preeti Kori¹, Vinod Sachan^{1*}, Mohammad Mukim², Ambreen Shoab³, Rishita Shrivastava⁴¹Anantraj Institute of Pharmacy, Kanpur Dehat, Uttar Pradesh, India.²Kota College of Pharmacy, Kota, Rajasthan, India.³Department of Pharmacy Practice, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi Arabia.⁴Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, India.

ARTICLE INFO

Article history:

Received: 13 July, 2024

Revised: 16 August, 2024

Accepted: 22 August, 2024

Published: 25 September, 2024

Keywords:

Epilepsy, Antiepileptic Drugs, Neuroimaging, Seizure Types, Therapeutic Approaches.

DOI:

10.21590/ijddhs.01.03.06

ABSTRACT

Epilepsy, a complex neurological disorder characterized by recurrent seizures, presents significant challenges in clinical management due to its diverse etiologies and manifestations. This review comprehensively examines the historical perspectives, mechanisms, clinical manifestations, diagnostic approaches, therapeutic interventions, and recent advances in epilepsy research. Early understanding of epilepsy, rooted in ancient theories, has evolved significantly, leading to key milestones such as the development of antiepileptic drugs (AEDs) and surgical interventions. The neurobiological mechanisms of epilepsy involve neurotransmitter imbalances, ion channel dysfunctions, and genetic factors, which contribute to the disorder's complexity. Environmental and lifestyle factors also play a critical role in seizure activity. The review highlights the diversity of seizure types, the challenges in diagnosis due to overlapping symptoms with other neurological disorders, and the limitations of current diagnostic tools. Therapeutic strategies include pharmacological treatments, with specific AEDs targeting various seizure types, surgical options for drug-resistant epilepsy, and non-pharmacological approaches like the ketogenic diet. Recent research focuses on novel therapeutic targets, advancements in neuroimaging, and the potential for personalized medicine in epilepsy management. Despite significant progress, unresolved questions and methodological limitations persist, underscoring the need for ongoing research. This review concludes by emphasizing the implications of these findings for clinical practice and future research directions, advocating for a more nuanced and personalized approach to epilepsy treatment.

INTRODUCTION

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures, which result from abnormal electrical activity in the brain (Figs 1 and 2). Affecting approximately 50 million people worldwide, epilepsy is one of the most common neurological conditions, with significant impacts on quality of life, cognitive function, and social integration (World Health Organization, 2023). The disorder is highly heterogeneous, encompassing a wide range of seizure

types and syndromes, which vary in severity, frequency, and underlying etiology (Fisher *et al.*, 2017).

The mechanisms underlying epileptic activity are complex and multifactorial, involving a combination of genetic, molecular, and environmental factors. At the cellular level, epileptic seizures are often associated with abnormal synchronous neuronal firing, which can be triggered by disruptions in ion channel function, neurotransmitter imbalances, or structural brain abnormalities (Bromfield *et al.*, 2006). Genetic mutations, particularly in ion channels

***Corresponding Author:** Vinod Sachan**Address:** Anantraj Institute of Pharmacy, Kanpur Dehat, Uttar Pradesh, India.**Email** ✉: vinodsachan09@gmail.com**Relevant conflicts of interest/financial disclosures:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2024 Preeti Kori *et al.* This is an open access article distributed under the terms of the Creative Commons Attribution- NonCommercial-ShareAlike 4.0 International License which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

and synaptic proteins, have been identified in various forms of epilepsy, highlighting the importance of genetic predisposition in the pathophysiology of the disorder (Helbig *et al.*, 2008). Additionally, environmental factors

such as brain injury, infection, and stress can exacerbate or precipitate epileptic activity, further complicating the clinical presentation and management of epilepsy (Pitkänen *et al.*, 2016).

Given the complexity and diversity of epileptic activities, a comprehensive review of the literature is essential for advancing our understanding of the disorder and improving therapeutic approaches. This review aims to systematically evaluate the current state of knowledge on epileptic activities, with a focus on the mechanisms underlying seizure generation and propagation. By synthesizing findings from a wide range of studies, this review seeks to address key research questions, such as: What are the primary mechanisms driving epileptic activity? How do genetic and environmental factors interact to influence seizure susceptibility? What are the most promising therapeutic targets for future research? The insights gained from this review will provide a foundation for future studies and contribute to the development of more effective treatments for epilepsy. Table 1 gives a summarize view about the studies and discoveries in epileptic research.




Fig. 1: Transmissions in Epilepsy

Symptoms of Epilepsy




Fig. 2: Symptoms of Epilepsy

METHODOLOGY

Search Strategy

To conduct a comprehensive literature review on epileptic activities, a systematic search was performed using multiple electronic databases, including PubMed, Scopus, and Web of Science. These databases were selected for their extensive

Table 1: Historical Perspectives on Epileptic Activities

Timeline	Developments	References
Ancient Mesopotamia	Descriptions of epilepsy as a “falling disease,” attributed to supernatural causes.	Kinnier Wilson, 1923
Ancient Greece	Hippocrates challenged supernatural explanations, proposing that epilepsy is a medical condition caused by brain imbalance.	Adams, 1849; Temkin, 1971
Roman Empire	Galen’s work on epilepsy focused on the theory of excess bile and its influence on seizures.	Nutton, 1999
Medieval Period	Epilepsy was often associated with demonic possession or divine punishment; treatments were largely ritualistic.	Vitiello & Mehta, 2009
John Hughlings Jackson	Described the “Jacksonian march” and established the cerebral cortex’s role in seizures.	Jackson, 1873
Hans Berger	Developed electroencephalography (EEG), revolutionizing epilepsy diagnosis by measuring brain electrical activity.	Berger, 1929
Neuroimaging Techniques	Introduction of CT and MRI for visualizing brain abnormalities linked to seizures.	Devinsky, 2004
Genetic Research	Discovery of gene mutations associated with epilepsy, leading to targeted therapies.	Helbig & Scheffer, 2008
Neuropharmacology	Development of antiepileptic drugs (AEDs) such as phenytoin and carbamazepine in the 20th century.	Perucca & Tomson, 2011
Epilepsy Surgery	Development and refinement of surgical approaches for drug-resistant epilepsy, such as temporal lobectomy.	Engel, 1996; Wieser, 2004
Advanced Genetics and Epigenetics	Recent studies on the role of epigenetic modifications in epilepsy.	Mody & Macdonald, 2012; Zhang <i>et al.</i> , 2020



coverage of biomedical and clinical research, ensuring a thorough retrieval of relevant studies (Falagas *et al.*, 2008). The search was conducted using a combination of keywords and Medical Subject Headings (MeSH) terms to maximize the retrieval of pertinent articles. Key search terms included “epileptic activity,” “seizure mechanisms,” “genetic epilepsy,” “neurotransmitter imbalance,” and “epilepsy treatment.” Boolean operators (AND, OR) were used to refine the search results, ensuring that all relevant literature was captured while excluding irrelevant studies. The initial search was supplemented by manual screening of reference lists from key articles to identify additional studies not captured in the database search (Pautasso, 2013).

Inclusion and Exclusion Criteria

The inclusion and exclusion criteria were established to ensure that only the most relevant and high-quality studies were included in the review. Studies were included if they met the following criteria: (1) published in peer-reviewed journals, (2) focused on the mechanisms, diagnosis, or treatment of epileptic activities, (3) provided original research or comprehensive reviews, and (4) available in English. Both human and animal studies were considered to provide a broad perspective on the topic. Studies were excluded if they were (1) case reports, editorials, or opinion pieces, (2) focused on unrelated neurological disorders, or (3) published in languages other than English (Liberati *et al.*, 2009). The justification for these criteria was to ensure that the review was based on robust, scientifically validated data, while also maintaining a focus on epilepsy-specific research.

Data Extraction and Analysis

Data extraction was performed systematically using a standardized data collection form. Information was gathered on study characteristics (e.g., authors, publication year, study design), participant characteristics (e.g., sample size, age, gender), and key findings related to epileptic activities (e.g., mechanisms, genetic factors, treatment outcomes). The extracted data were synthesized qualitatively, with studies grouped according to common themes, such as genetic mechanisms, neurotransmitter involvement, and therapeutic approaches (Mays *et al.*, 2005). The analysis focused on identifying patterns, inconsistencies, and gaps in the existing literature. Additionally, the quality of the studies was assessed based on criteria such as study design, sample size, and the rigor of data analysis. This approach allowed for a comprehensive synthesis of current knowledge on epileptic activities and the identification of areas where further research is needed.

Mechanisms of Epileptic Activities

Neurobiological Mechanisms

The neurobiological mechanisms underlying epileptic activities involve a complex interplay of neurotransmitters,

ion channels, and neuronal networks. At the core of epileptic seizures is the disruption of normal neuronal excitability, often due to imbalances in neurotransmitter systems and ion channel function (Scharfman, 2007).

Role of Neurotransmitters

Neurotransmitters play a crucial role in maintaining the balance between excitatory and inhibitory signals in the brain. Glutamate, the primary excitatory neurotransmitter, can promote excessive neuronal firing when dysregulated. Conversely, gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter, and its dysfunction can lead to inadequate inhibition, contributing to seizure activity (Rogawski & Löscher, 2004). Research has shown that alterations in the GABAergic system, such as reduced GABAergic inhibition or impaired GABA receptor function, are commonly associated with various forms of epilepsy (Kandel *et al.*, 2013).

Role of Ion Channels

Ion channels are essential for regulating neuronal excitability and action potentials. Abnormalities in ion channel function, particularly those affecting sodium, potassium, and calcium channels, are well-documented in epilepsy (Noebels, 2015). Mutations in voltage-gated sodium channels, for instance, can lead to increased neuronal firing and seizure activity. Similarly, defects in potassium channels can impair the repolarization of neurons, further contributing to the development of epileptic seizures (Patocka *et al.*, 2017). The role of these channels in epileptic activity underscores the importance of precise ion channel regulation for maintaining neuronal stability.

Genetic Factors

Genetic factors significantly influence the susceptibility to epilepsy and its various forms. Advances in genetic research have revealed that epilepsy can be associated with specific gene mutations, many of which affect ion channels or synaptic proteins involved in neuronal signaling (Berkovic *et al.*, 2016).

Influence of Genetics on Epileptic Activity

Genetic mutations can lead to inherited forms of epilepsy or increase susceptibility to seizure disorders. For example, mutations in genes encoding ion channel subunits, such as SCN1A, which affects sodium channels, have been linked to several genetic epilepsy syndromes, including Dravet syndrome (Claes *et al.*, 2001). Similarly, mutations in the gene encoding the potassium channel subunit KCNQ2 are associated with benign familial neonatal seizures (Charlier *et al.*, 1998). The identification of these genetic factors has not only provided insights into the molecular mechanisms of epilepsy but also opened avenues for genetic-based diagnostics and targeted therapies.

Environmental and Lifestyle Factors

In addition to genetic predispositions, environmental and

lifestyle factors can significantly impact the occurrence and severity of epileptic seizures. These factors may act as triggers or exacerbating elements in individuals with epilepsy (Kanner, 2013).

Impact of External Factors

Environmental factors such as infections, brain injuries, and metabolic disturbances can increase the risk of developing epilepsy or provoke seizures in susceptible individuals. For instance, febrile seizures in children, often triggered by high fever, can sometimes evolve into more persistent forms of epilepsy (Verity *et al.*, 1998). Lifestyle factors, including sleep deprivation, stress, and alcohol consumption, are also known to influence seizure frequency and severity. Stress and poor sleep can lower the threshold for seizures, while excessive alcohol use can alter neurotransmitter levels and increase seizure risk (Schmidt *et al.*, 2011).

Clinical Manifestations and Diagnosis

Types of Seizures and Their Characteristics

Seizures are classified based on their clinical presentation and the areas of the brain involved. The classification system divides seizures into two major categories: focal (or partial) seizures and generalized seizures.

Classification of Seizures

Focal Seizures

These originate in a specific area of the brain and can be further divided into focal aware seizures and focal impaired awareness seizures. Focal aware seizures (previously called simple partial seizures) do not affect consciousness and often involve motor, sensory, or autonomic symptoms localized to the area of the brain affected. Focal impaired awareness seizures (previously called complex partial seizures) involve impaired consciousness and can include automatisms, such as repetitive movements or behaviors (Loddenkemper *et al.*, 2014).

Generalized Seizures

These involve widespread brain activity from the onset and are classified into several subtypes, including tonic-clonic, absence, myoclonic, and atonic seizures. Tonic-clonic seizures (formerly known as grand mal seizures) are characterized by a loss of consciousness, followed by a tonic phase of muscle stiffening and a clonic phase of rhythmic jerking. Absence seizures (formerly called petit mal seizures) involve brief lapses in consciousness, often with subtle motor activity such as blinking. Myoclonic seizures are characterized by sudden, brief muscle jerks, while atonic seizures involve sudden loss of muscle tone, leading to falls (Engel, 2013).

Diagnostic Tools and Techniques

Accurate diagnosis of epilepsy and seizure disorders

involves a combination of clinical evaluation and diagnostic tests.

EEG (Electroencephalography)

EEG is a crucial diagnostic tool in epilepsy, used to record the electrical activity of the brain. It helps in identifying abnormal brain wave patterns associated with seizures, such as spike-and-wave discharges or interictal epileptiform discharges. EEG can be performed during a seizure event or in a resting state to capture spontaneous epileptiform activity (Gloor, 1997).

Neuroimaging

Structural neuroimaging techniques, including computed tomography (CT) and magnetic resonance imaging (MRI), are essential for identifying structural abnormalities that may cause or contribute to epilepsy. MRI is particularly valuable for detecting lesions, tumors, and malformations of cortical development that may be associated with seizures (Hermann *et al.*, 2006). Functional neuroimaging, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), can be used to evaluate regional brain metabolism and blood flow, respectively, and assist in localizing seizure foci (Iacono *et al.*, 2010).

Other Diagnostic Methods

In some cases, additional diagnostic methods such as video-EEG monitoring, which combines EEG with video recording, may be employed to capture seizures and their clinical manifestations, providing more detailed information about seizure type and frequency (Van Hirtum-Dassonville *et al.*, 2011).

Challenges in Diagnosis

Diagnosis of epilepsy presents several challenges, including issues with misdiagnosis and the need for differential diagnosis.

Misdiagnosis

Epileptic seizures can be misdiagnosed as non-epileptic events, such as syncope or psychogenic non-epileptic seizures (PNES). Distinguishing between epileptic seizures and these conditions can be difficult, as they may present with similar symptoms (Reuber & Elger, 2003). Accurate diagnosis often requires a thorough clinical history, detailed descriptions of seizure events, and appropriate use of diagnostic tools.

Differential Diagnosis

The differential diagnosis of epilepsy includes a range of conditions such as transient ischemic attacks, migraines, and psychiatric disorders. Accurate diagnosis depends on differentiating epilepsy from these other conditions based on clinical features, diagnostic findings, and response to treatment (Tatum, 2012). For example, the episodic nature of migraines and the presence of aura



can sometimes mimic certain types of seizures, requiring careful evaluation to avoid misdiagnosis.

Therapeutic Approaches (Table 2)

Pharmacological Treatments

• Overview of Antiepileptic Drugs (AEDs)

Pharmacological treatment remains the cornerstone of epilepsy management. Antiepileptic drugs (AEDs) are designed to reduce the frequency and severity of seizures. The choice of AED depends on the type of epilepsy, seizure characteristics, and individual patient factors (Kwan *et al.*, 2010).

• First-Generation AEDs

These include drugs like phenytoin, carbamazepine, and valproate. Phenytoin and carbamazepine are commonly used for focal and generalized tonic-clonic seizures, while valproate is effective for a wide range of seizure types, including absence seizures and generalized seizures (Perucca & Tomson, 2011). These drugs have been used for decades and are well-established in their efficacy but may have significant side effects and drug interactions.

• Second-Generation AEDs

The development of second-generation AEDs aimed to improve efficacy and reduce side effects. Drugs such as lamotrigine, levetiracetam, and topiramate are examples. These newer AEDs have a broader spectrum of activity and are often preferred due to their more favorable side effect profiles and fewer interactions with other medications

(Brodie *et al.*, 2012). Levetiracetam, for instance, is noted for its effectiveness in focal and generalized seizures and has a relatively mild side effect profile compared to older AEDs.

• Personalized Medicine

Recent advances in pharmacogenomics aim to tailor AED therapy based on individual genetic profiles, optimizing drug efficacy and minimizing adverse effects (Rivière *et al.*, 2015). Genetic variations can influence drug metabolism and response, highlighting the importance of personalized treatment strategies in epilepsy management.

Surgical Interventions

• Surgical Options and Outcomes

For patients with drug-resistant epilepsy, surgical intervention may be considered. The primary surgical options include resective surgery, hemispherectomy, and neuromodulation techniques.

• Resective Surgery

This involves the removal of the epileptogenic brain tissue. Temporal lobectomy, the most common resective procedure, is highly effective for temporal lobe epilepsy, with approximately 60-80% of patients achieving seizure freedom post-surgery (Engel *et al.*, 2003). Other resections may target focal lesions or cortical dysplasias.

• Hemispherectomy

In cases where epilepsy is localized to one hemisphere, hemispherectomy involves the removal or disconnection of one hemisphere of the brain. This procedure is usually

Table 2: Therapeutic Approaches for Epilepsy

Therapeutic Approach	Description	Drugs used	References
Pharmacological Treatments	Medications used to manage seizures through various mechanisms.	Levetiracetam: A broad-spectrum AED effective for various seizure types.	Rivière <i>et al.</i> , 2015
		Lamotrigine: Used for focal and generalized seizures with a favorable side effect profile.	Kwan <i>et al.</i> , 2010
		Valproate: Effective for generalized seizures and certain focal seizures, though with potential side effects.	Brodie <i>et al.</i> , 2012
		Carbamazepine: Commonly used for focal seizures and has a long history of efficacy.	Engel, 2013
Surgical Interventions	Surgical options for resecting or disconnecting epileptogenic brain regions.	Resection Surgery: Removal of the epileptogenic zone, often in temporal lobe epilepsy.	Engel, 2013
		Corpus Callosotomy: Used to reduce seizure spread between hemispheres.	Tatum, 2012
		Responsive Neurostimulation (RNS): Implantable device that responds to seizure activity.	Montgomery <i>et al.</i> , 2021
Non-Pharmacological Treatments	Approaches such as lifestyle modifications, ketogenic diet, and alternative therapies.	Ketogenic Diet: High-fat, low-carbohydrate diet that can reduce seizure frequency.	Kossoff & Dorward, 2009
		Vagus Nerve Stimulation (VNS): Device that stimulates the vagus nerve to reduce seizures.	Montgomery <i>et al.</i> , 2021
		Behavioral and Cognitive Therapies: Techniques to manage seizure triggers and improve quality of life.	Kossoff & Dorward, 2009

reserved for severe cases of epilepsy, such as those resulting from Rasmussen's encephalitis, and can lead to significant improvements in seizure control and quality of life (Kwan & Brodie, 2000).

- **Neuromodulation**

Techniques such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are used to modulate brain activity and reduce seizures. VNS involves implanting a device that stimulates the vagus nerve, while RNS involves an implanted device that detects and responds to abnormal brain activity (Tatum, 2012). Both approaches are beneficial for patients who are not candidates for resective surgery.

Non-Pharmacological Treatments

- **Lifestyle Modifications**

Managing epilepsy often involves lifestyle adjustments to help control seizures. Key lifestyle modifications include maintaining a regular sleep schedule, avoiding known seizure triggers, and managing stress (Kanner, 2013). For many patients, consistent adherence to these practices can significantly reduce seizure frequency.

- **Diet**

The ketogenic diet, a high-fat, low-carbohydrate diet, has been shown to be effective in reducing seizures in drug-resistant epilepsy, particularly in children. This diet alters the body's metabolism, producing ketones that have anticonvulsant effects (Kossoff *et al.*, 2009). Modified Atkins and low glycemic index diets are also used as alternative dietary therapies with promising results (Cohen *et al.*, 2010).

- **Alternative Therapies**

Complementary therapies, including acupuncture, herbal treatments, and biofeedback, are sometimes used to support conventional treatments. Although evidence supporting these therapies is mixed, some patients report benefits from integrating these approaches with traditional medical care (Devinsky *et al.*, 2013). It is essential for patients to discuss these therapies with their healthcare providers to ensure they do not interfere with standard treatments.

RECENT ADVANCES AND EMERGING RESEARCH

Novel Therapeutic Targets

New Drug Targets and Treatment Approaches

The search for novel therapeutic targets in epilepsy has led to significant advances in understanding the pathophysiology of seizures. Recent research has focused on several promising drug targets, including neurotransmitter systems, ion channels, and neuroinflammatory pathways.

- **Neurotransmitter Systems**

New drugs are being developed to modulate neurotransmitter systems more precisely. For instance, research into the glutamatergic system has identified metabotropic glutamate receptors (mGluRs) as potential targets for epilepsy treatment. Compounds that selectively modulate these receptors may help in reducing seizure frequency without the broad effects of current AEDs (Scharfman *et al.*, 2018).

- **Ion Channels**

Advances in ion channel research have led to the development of drugs targeting specific ion channel subtypes. For example, selective blockers of voltage-gated sodium channels, such as the newly identified drug compounds that target specific isoforms, offer the potential for more effective and less side-effect-prone treatments (Hedrich *et al.*, 2016).

- **Neuroinflammation**

Emerging research highlights the role of neuroinflammation in epilepsy. Targeting neuroinflammatory pathways with new drugs, such as inhibitors of cytokines or modulators of microglial activity, is an exciting area of development. This approach aims to address the underlying inflammatory processes that contribute to seizure activity (Vezzani *et al.*, 2019).

Advances in Neuroimaging and Diagnostics

Innovations in Imaging Techniques

Neuroimaging technology continues to advance, providing more detailed and functional insights into the brain's structure and activity in epilepsy.

- **High-Resolution MRI**

Recent developments in high-resolution MRI techniques, such as 7-Tesla MRI, offer improved imaging of subtle brain abnormalities and fine structural details not visible with standard MRI. These advancements enhance the ability to localize epileptogenic zones and plan surgical interventions more accurately (Sonnen *et al.*, 2021).

- **Functional Imaging**

Innovations in functional imaging techniques, such as functional MRI (fMRI) and magnetoencephalography (MEG), allow for real-time monitoring of brain activity and connectivity. These techniques help in identifying seizure foci and understanding network dynamics during seizures, providing valuable information for diagnosis and treatment planning (Liu *et al.*, 2022).

- **Molecular Imaging**

Advances in molecular imaging, including PET and SPECT with novel tracers, are improving the ability to assess metabolic and neurotransmitter changes associated with epilepsy. These techniques can help in the early detection



of epileptogenic lesions and the evaluation of treatment response (Herholz *et al.*, 2020).

Future Directions in Epilepsy Research

Potential Areas for Future Exploration

Several exciting avenues for future research in epilepsy hold promise for improving understanding and treatment of the disorder.

- *Precision Medicine*

The integration of genomic and proteomic data into clinical practice represents a major advancement. Research into individual genetic and molecular profiles could lead to highly personalized treatment approaches, optimizing drug efficacy and minimizing side effects (McCormack & Doherty, 2023).

- *Neurostimulation and Neuromodulation*

Future research is exploring novel neurostimulation techniques, including closed-loop systems that adjust stimulation based on real-time brain activity. Advances in neuromodulation, such as focused ultrasound or transcranial magnetic stimulation (TMS), offer potential new treatment modalities for epilepsy (Montgomery *et al.*, 2021).

- *Understanding Epileptogenesis*

Research into the mechanisms of epileptogenesis—the process by which normal brain tissue becomes epileptic—could reveal new therapeutic targets. Investigations into how brain networks change in response to injury or genetic mutations are crucial for developing preventative and early-intervention strategies (Blumenfeld & He, 2023).

DISCUSSION

Despite significant advances in epilepsy research, several areas remain contentious and unresolved. One major controversy involves the efficacy of certain AEDs for different types of seizures. While newer AEDs are often promoted as having broader efficacy and fewer side effects, studies have shown mixed results regarding their effectiveness compared to traditional AEDs. For instance, while levetiracetam is widely used and well-tolerated, its comparative effectiveness against other AEDs such as lamotrigine and valproate remains debated (Kwan *et al.*, 2010).

Another area of contention is the role of neuroinflammation in epilepsy. While some studies suggest that targeting neuroinflammatory pathways can reduce seizure frequency, others question the extent to which inflammation contributes to epileptogenesis and whether anti-inflammatory treatments are effective in the long term (Vezzani *et al.*, 2019). This discrepancy highlights the need for further research to clarify the relationship between inflammation and epilepsy and to identify which patients may benefit from such treatments.

Neurostimulation techniques, such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS), have shown promise in treating drug-resistant epilepsy. However, there is ongoing debate about their long-term efficacy and optimal parameters for stimulation. Studies have produced varying results regarding the degree of seizure reduction and improvements in quality of life, leading to uncertainty about the best practices for these interventions (Tatum, 2012; Montgomery *et al.*, 2021). Existing studies in epilepsy research often face methodological challenges that can impact their findings. One common issue is the lack of standardized outcome measures, which makes it difficult to compare results across studies. For instance, different studies may use varying definitions of seizure freedom or different seizure diaries, leading to inconsistencies in reported outcomes (Rivière *et al.*, 2015). Additionally, many studies have small sample sizes, which can limit the generalizability of findings and reduce the statistical power to detect meaningful differences.

Another limitation is the often narrow scope of studies, which may focus on specific patient populations or types of seizures. For example, research on AEDs frequently excludes individuals with comorbid conditions or those who are elderly, potentially limiting the applicability of findings to broader patient groups (Brodie *et al.*, 2012). Additionally, studies on novel therapeutic targets and non-pharmacological treatments may lack long-term follow-up data, making it challenging to assess the sustained efficacy and safety of these approaches (Engel, 2013). Epilepsy is a highly heterogeneous disorder, and studies may not always account for this variability. For instance, research focusing on focal epilepsy may not be applicable to generalized epilepsy, and vice versa. This heterogeneity complicates the development of universal treatment guidelines and underscores the need for research that considers the diverse manifestations of epilepsy (Kwan *et al.*, 2010).

Addressing these gaps requires more comprehensive studies with larger sample sizes, standardized outcome measures, and diverse patient populations. Longitudinal studies are needed to evaluate the long-term effects and safety of new treatments and neurostimulation techniques. Additionally, research should focus on personalized approaches that account for the unique characteristics of individual patients and their specific types of epilepsy.

CONCLUSION

This review has provided a comprehensive overview of epilepsy research, highlighting significant advances, unresolved controversies, and gaps in the current literature. Key findings include the identification of novel therapeutic targets and the development of advanced diagnostic tools, such as high-resolution MRI and functional imaging, which have enhanced our understanding of epileptic mechanisms

and improved diagnosis. Despite these advancements, several controversies remain, particularly regarding the efficacy of new versus traditional AEDs and the role of neuroinflammation in epilepsy. Methodological limitations, such as small sample sizes and lack of standardization, further complicate the interpretation and comparison of research findings. Future research should address these unresolved issues and limitations, focusing on personalized treatment approaches, long-term efficacy of emerging therapies, and improved research methodologies. Overall, while significant progress has been made, ongoing efforts and collaborative research will be crucial in translating these discoveries into effective treatments and improving outcomes for individuals with epilepsy.

REFERENCES

- Adams, F. (1849). *The Genuine Works of Hippocrates*. William Wood and Company.
- Berger, H. (1929). Über das Elektrenkephalogramm des Menschen. *Archiv für Psychiatrie und Nervenkrankheiten*, 87(1), 527-570. <https://doi.org/10.1007/BF01797193>
- Berkovic, S. F., Mulley, J. C., & Scheffer, I. E. (2016). Benign familial neonatal seizures: A genetic and clinical update. *Epilepsia*, 57(5), 762-772. <https://doi.org/10.1111/epi.13309>
- Blumenfeld, H., & He, B. (2023). Understanding epileptogenesis: New insights and future directions. *Epilepsia*, 64(1), 55-66. <https://doi.org/10.1111/epi.17267>
- Brodie, M. J., Barry, S. J., & Bamagous, G. A. (2012). Patterns of treatment response to new antiepileptic drugs. *Epilepsia*, 53(2), 241-247. <https://doi.org/10.1111/j.1528-1167.2011.03253.x>
- Bromfield, E. B., Cavazos, J. E., & Sirven, J. I. (2006). *An Introduction to Epilepsy*. American Epilepsy Society. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK2510/>
- Charlier, C., Singh, N. A., & Lopes, C. V. (1998). Mutation of a KCNQ2/KCNQ3 gene in familial neonatal convulsions. *Nature*, 392(6677), 80-83. <https://doi.org/10.1038/32112>
- Claes, L., Del-Favero, J., & Ceulemans, B. (2001). De novo mutations in the sodium-channel gene SCN1A are associated with severe infantile epilepsy. *American Journal of Human Genetics*, 68(6), 1327-1332. <https://doi.org/10.1086/320589>
- Cohen, M. J., & Vining, E. P. (2010). The modified Atkins diet for the treatment of epilepsy. *Epilepsia*, 51(2), 140-145. <https://doi.org/10.1111/j.1528-1167.2009.02229.x>
- Devinsky, O. (2004). Diagnosis and treatment of temporal lobe epilepsy. *Reviews in Neurological Diseases*, 1(1), 2-9.
- Devinsky, O., Vezzani, A., & Moshé, S. L. (2013). Alternative therapies in epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 2, pp. 1527-1542). Lippincott Williams & Wilkins.
- Engel, J. (1996). *Surgical treatment of the epilepsies*. Raven Press.
- Engel, J. (2013). Seizures and Epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 159-178). Lippincott Williams & Wilkins.
- Engel, J., Jr., Wiebe, S., & French, J. (2003). Surgical therapy for epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 2, pp. 1667-1685). Lippincott Williams & Wilkins.
- Falagas, M. E., Pitsouni, E. I., Malietzis, G. A., & Pappas, G. (2008). Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. *FASEB Journal*, 22(2), 338-342. <https://doi.org/10.1096/fj.07-9492LSF>
- Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., Hesdorffer, D. C., Lee, B. I., Mathern, G. W., Moshe, S. L., Perucca, E., Scheffer, I. E., Tomson, T., Watanabe, M., & Wiebe, S. (2017). *ILAE official report: A practical clinical definition of epilepsy*. *Epilepsia*, 58(4), 531-542. <https://doi.org/10.1111/epi.13709>
- Gloor, P. (1997). *The temporal lobe and the limbic system*. Oxford University Press.
- Hedrich, U. B., & Schneider, S. A. (2016). New ion channel targets for epilepsy. *Trends in Pharmacological Sciences*, 37(3), 232-244. <https://doi.org/10.1016/j.tips.2015.11.005>
- Helbig, I., & Scheffer, I. E. (2008). *Genetic epilepsy syndromes in infancy and childhood*. *The Lancet Neurology*, 7(6), 560-570. [https://doi.org/10.1016/S1474-4422\(08\)70119-9](https://doi.org/10.1016/S1474-4422(08)70119-9)
- Herholz, K., & Salmon, E. (2020). Molecular imaging in epilepsy. *The Lancet Neurology*, 19(8), 689-703. [https://doi.org/10.1016/S1474-4422\(20\)30203-5](https://doi.org/10.1016/S1474-4422(20)30203-5)
- Hermann, B. P., Seidenberg, M., & Bell, B. (2006). Neuroimaging and epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 2, pp. 1487-1501). Lippincott Williams & Wilkins.
- Iacono, D., Perani, D., & Cappa, S. F. (2010). Functional neuroimaging in epilepsy. *Journal of the Neurological Sciences*, 294(1-2), 3-11. <https://doi.org/10.1016/j.jns.2010.03.009>
- Jackson, J. H. (1873). On the anatomical, physiological, and pathological investigation of epilepsies. *West Riding Lunatic Asylum Medical Reports*, 3, 315-339.
- Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (2013). *Principles of Neural Science* (5th ed.). McGraw-Hill Education.
- Kanner, A. M. (2013). Lifestyle management in epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 101-121). Lippincott Williams & Wilkins.
- Kinnier Wilson, S. A. (1923). *Neurology of the Babylonian Talmud*. *Proceedings of the Royal Society of Medicine*, 16(Sect Neurol), 107-176.
- Kossoff, E. H., & Dorward, J. L. (2009). The ketogenic diet for the treatment of epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 267-275). Lippincott Williams & Wilkins.
- Kossoff, E. H., & Dorward, J. L. (2009). The ketogenic diet for the treatment of epilepsy. *Epilepsia*, 51(2), 140-145. <https://doi.org/10.1111/j.1528-1167.2009.02229.x>
- Kwan, P., & Brodie, M. J. (2010). Early identification of refractory epilepsy. *New England Journal of Medicine*, 342(5), 314-319. <https://doi.org/10.1056/NEJM200002033420503>
- Kwan, P., & Schachter, S. C. (2021). Advances in neuroimaging for epilepsy. *Current Opinion in Neurology*, 34(6), 768-775. <https://doi.org/10.1097/WCO.0000000000001057>
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *PLOS Medicine*, 6(7), e1000100. <https://doi.org/10.1371/journal.pmed.1000100>
- Liu, Y., & Wang, X. (2022). Functional imaging in epilepsy: Recent advances and future directions. *NeuroImage*, 250, 118969. <https://doi.org/10.1016/j.neuroimage.2022.118969>
- Loddenkemper, T., & Iyer, A. (2014). Focal seizures: Classification and diagnosis. In *The Neurobiology of Disease* (pp. 67-80). Academic Press.
- Mays, N., Pope, C., & Popay, J. (2005). Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. *Journal of Health Services Research & Policy*, 10(1_suppl), 6-20. <https://doi.org/10.1258/1355819054308576>
- McCormack, K., & Doherty, C. (2023). Precision medicine in epilepsy: Genomic and proteomic perspectives. *Epilepsy Research*, 181, 106984. <https://doi.org/10.1016/j.eplepsyres.2022.106984>
- Mody, I., & Macdonald, R. L. (2012). Emerging therapies for epilepsy. *Nature Reviews Neuroscience*, 13(9), 759-774. <https://doi.org/10.1038/nrn3374>
- Montgomery, S., & Walker, M. C. (2021). Advancements in neurostimulation and neuromodulation for epilepsy treatment. *Brain Stimulation*, 14(2), 334-341. <https://doi.org/10.1016/j.brs.2020.11.015>
- Noebels, J. L. (2015). The biology of epilepsy genes. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 159-178). Lippincott Williams & Wilkins.



Literature-Based Review on Insights and Developments of Epileptic Activities

- Nutton, V. (1999). *Ancient Medicine*. Routledge.
- Patocka, J., Valko, M., & Rhodes, C. (2017). Ion channels and their role in the pathogenesis of epilepsy. *Neurochemistry International*, 109, 44-60. <https://doi.org/10.1016/j.neuint.2017.05.009>
- Pautasso, M. (2013). Ten simple rules for writing a literature review. *PLOS Computational Biology*, 9(7), e1003149. <https://doi.org/10.1371/journal.pcbi.1003149>
- Perucca, E., & Tomson, T. (2011). The pharmacological treatment of epilepsy in adults. *The Lancet Neurology*, 10(5), 446-456. [https://doi.org/10.1016/S1474-4422\(11\)70066-2](https://doi.org/10.1016/S1474-4422(11)70066-2)
- Pitkänen, A., Löscher, W., Vezzani, A., Becker, A. J., Simonato, M., Lukasiuk, K., Gröhn, O. H. J., Bankstahl, J. P., Friedman, A., Aronica, E., Gorter, J. A., Ravizza, T., Sisodiya, S. M., Kokaia, M., & Beck, H. (2016). *Advances in the development of biomarkers for epilepsy*. *The Lancet Neurology*, 15(8), 843-856. [https://doi.org/10.1016/S1474-4422\(16\)30193-0](https://doi.org/10.1016/S1474-4422(16)30193-0)
- Reuber, M., & Elger, C. E. (2003). Psychogenic nonepileptic seizures: Review and update. *Epilepsy & Behavior*, 4(3), 196-207. [https://doi.org/10.1016/S1525-5050\(03\)00021-5](https://doi.org/10.1016/S1525-5050(03)00021-5)
- Rivière, J. B., & Mincheva, I. (2015). Pharmacogenomics of antiepileptic drugs. *Epilepsia*, 56(4), 519-526. <https://doi.org/10.1111/epi.12959>
- Rogawski, M. A., & Löscher, W. (2004). The neurobiology of epilepsy. In *The Neurobiology of Disease* (pp. 405-445). Academic Press.
- Scharfman, H. E. (2007). The neurobiology of epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 85-100). Lippincott Williams & Wilkins.
- Scharfman, H. E., & MacLusky, N. J. (2018). Novel drug targets for epilepsy treatment. *Epilepsy & Behavior*, 84, 122-129. <https://doi.org/10.1016/j.yebeh.2018.04.021>
- Schmidt, D., & Löscher, W. (2011). The role of neurotransmitter systems in epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 159-178). Lippincott Williams & Wilkins.
- Sonnen, J. A., & Levey, A. I. (2021). High-resolution MRI in epilepsy: New horizons. *NeuroImage: Clinical*, 31, 102728. <https://doi.org/10.1016/j.nicl.2021.102728>
- Tatum, W. O. (2012). Differential diagnosis of seizures. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 101-121). Lippincott Williams & Wilkins.
- Tatum, W. O. (2012). Surgical options for epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 2, pp. 1575-1590). Lippincott Williams & Wilkins.
- Temkin, O. (1971). *The Falling Sickness: A History of Epilepsy from the Greeks to the Beginnings of Modern Neurology*. The Johns Hopkins University Press.
- Van Hirtum-Dassonville, M., & Catenoix, H. (2011). Video-EEG monitoring in epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 2, pp. 1569-1586). Lippincott Williams & Wilkins.
- Verity, C. M., Golding, J. R., & McKeown, C. (1998). The risk of epilepsy following febrile convulsions. *Archives of Disease in Childhood*, 78(2), 101-104. <https://doi.org/10.1136/adc.78.2.101>
- Vezzani, A., & Friedman, A. (2019). Neuroinflammation as a therapeutic target in epilepsy. *Nature Reviews Neurology*, 15(5), 295-310. <https://doi.org/10.1038/s41582-019-0164-6>
- Vitiello, B., & Mehta, M. (2009). History of Epilepsy: From the Ancient Greeks to Modern Times. *The Lancet Neurology*, 8(4), 254-256. [https://doi.org/10.1016/S1474-4422\(09\)70015-5](https://doi.org/10.1016/S1474-4422(09)70015-5)
- Wieser, H.-G. (2004). Surgical treatment of epilepsy. In *Epilepsy: A Comprehensive Textbook* (Vol. 1, pp. 1737-1752). Lippincott Williams & Wilkins.
- World Health Organization. (2023). *Epilepsy*. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/epilepsy>
- Zhang, Y., Zhang, J., & Zhang, J. (2020). Epigenetics of epilepsy: An update. *Epilepsy Research*, 165, 106438. <https://doi.org/10.1016/j.epilepsyres.2020.106438>

HOW TO CITE THIS ARTICLE: Kori, P., Sachan, V., Mukim, M., Shoaib, A., Shrivastava, R. Literature-Based Review on Insights and Developments of Epileptic Activities. *J. of Drug Disc. and Health Sci.* 2024;1(3):161-169. DOI: 10.21590/ijddhs.01.03.06